XL999 Administered Intravenously to a Subject With Advanced Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01945164|
Expanded Access Status : No longer available
First Posted : September 18, 2013
Last Update Posted : October 21, 2014
Cancer is a worldwide clinical and economic problem. Conventional approaches to treating cancer include surgery, radiotherapy, and cytotoxic chemotherapy as single modalities or as combined therapies. Recently, targeted therapies including antibodies and small molecule inhibitors have also demonstrated clinical benefit. It is now possible to study different genetic lesions involved in cancer types due to advances in genomic methodologies. The investigational drug in this study, XL999 inhibits multiple receptor tyrosine kinases, including VEGF receptor (VEGFR2/KDR), platelet derived growth factor receptors (PDGFRβ), fms-like tyrosine kinase receptor 3 (FLT3), fibroblast growth factor receptors (FGFR1, FGFR3), RET, and KIT, and thus, interferes with multiple cellular processes simultaneously and will likely have effects on the integrity of tumor neovasculature and angiogenesis. Together with the ability to induce a novel cell cycle arrest, the spectrum of activities that XL999 exhibits may reduce both tumor cell proliferation and angiogenesis in the clinic.
The rationale and purpose of this maintenance study is to allow a subject receiving clinical benefit from XL999 to continue treatment.
|Condition or disease||Intervention/treatment|
|Advanced Malignancy||Drug: XL999|
|Study Type :||Expanded Access|
|Official Title:||Single Patient Treatment Study for the Use of XL999 Administered Intravenously to a Subject With Advanced Malignancies Previously Enrolled in Study XL999-900|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
- Drug: XL999
The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01945164
|United States, Texas|
|Cancer Therapy and Research Center at UTHSCSA|
|San Antonio, Texas, United States, 78229|
|Principal Investigator:||John Sarantopoulos, MD||University of Texas Health Science Center San Antonio|